CytoBoost is a new, premium approach to cell culture, offering laboratories a way to enhance the health and performance of their cells. With this innovative product, you can think of CytoBoost as a dedicated solution designed specifically to address common challenges in cell culture. The formula is crafted to provide cells with the essential support they need, ensuring optimal function and more consistent results in laboratory processes.
CytoBoost Media Additives are available in five specialised formulations, each developed to meet a specific need in cell care. For structural support, the Develop formulation promotes a strong extracellular matrix, essential for healthy growth and cellular structure. For laboratories aiming for higher proliferation rates, Maximise helps cells multiply quickly and efficiently, ideal for optimising experimental results. If recovery after freeze-thaw cycles is critical, Revive enhances cell viability during revival, adding support for increased survival rates post-thaw. Perform is the go-to solution for general cell culture applications, providing well-rounded support across various processes, while Vision is formulated with corneal cells in mind, enhancing their vitality and performance.
As CytoBoost launches, the company is inviting laboratories, scientists, and educational institutions to take part in their Research With Us programme, a collaboration aimed at exploring CytoBoost’s full potential. This exclusive opportunity is available for a limited time and is designed to bring together professionals across research sectors. By joining, participants can work closely with the CytoBoost team to expand their research possibilities with these innovative cell care solutions.
For those interested in participating, simply reach out to the CytoBoost team, and they’ll guide you through the enrolment process. This programme represents a unique opportunity to engage with a groundbreaking approach to cell culture care, so don’t hesitate to get involved.
BSF Enterprise plc (LON:BSFA), the owner of pioneering UK-based clinical and cellular agriculture company 3D Bio-Tissues, is unlocking the next generation of biotech solutions. It is achieving this through an acquisition-led growth strategy to drive the development of lab-grown tissues.
